Eli Lilly said its experimental oral GLP-1 drug orforglipron outperformed Novo Nordisk’s oral semaglutide in a head-to-head phase 3 trial.
In a 52-week study involving 1,698 adults with Type 2 diabetes, the highest dose of orforglipron lowered average blood sugar by 2.2%, compared with 1.4% for the highest dose of oral semaglutide, according to a Sept. 17 news release from Eli Lilly.
The highest dose of Eli Lilly’s drug also resulted in patients losing an average of 9.2% of their weight, compared to 5.3% weight loss with Novo Nordisk’s pill.
Orforglipron has also shown clinical improvement across cardiovascular risk factors, including non-HDL cholesterol, systolic blood pressure and triglycerides, the release said.
Novo Nordisk, meanwhile, plans to seek FDA approval for its high-dose version of Wegovy, Bloomberg reported Sept. 16. Martin Holst Lange, MD, PhD, Novo Nordisk’s chief scientific officer, said high-dose Wegovy offers the same weight loss potential as Eli Lilly’s Zepbound.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.